Key facts
- This page summarizes Erez Chimovits's Form 4 filing for ADARx Pharmaceuticals, Inc. (ADRX).
- 9 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 30 Sep 2026, 17:29.
Erez Chimovits - 28 Sep 2026 Form 4 Insider Report for ADARx Pharmaceuticals, Inc. (ADRX)
- Reporting relationship
- Director
- Issuer ticker
- ADRX
- Reported as of
- 28 Sep 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 30 Sep 2026, 17:29:36 UTC
- Prior SEC filing
- 24 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Erez Chimovits
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Erez Chimovits filed Form 4 for ADARx Pharmaceuticals, Inc. (ADRX) on 30 Sep 2026.
Change
- Previous filing in this sequence was filed on 24 Sep 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001706399
Primary reporting owner
Chimovits Erez
- Relationship
- Director
- Address
- C/O ADARX PHARMACEUTICALS, INC., 5871 OBERLIN DRIVE, SUITE 200, SAN DIEGO
- Signature
- /s/ Erez Chimovits
- Signature date
- 30 Sep 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADRX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +7,127,019
- Change %
- Price
- Shares after
- 7,127,019
- Date
- 28 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
ADRX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +1,333,975
- Change %
- +19%
- Price
- Shares after
- 8,460,994
- Date
- 28 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
ADRX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +513,067
- Change %
- +6.1%
- Price
- Shares after
- 8,974,061
- Date
- 28 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
ADRX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +256,448
- Change %
- +2.9%
- Price
- Shares after
- 9,230,509
- Date
- 28 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F1, F3, F4
ADRX
transaction
Common Stock
Purchase
- Transaction value
- Shares
- +61,516
- Change %
- +0.67%
- Price
- $17.00*
- Shares after
- 9,292,025
- Date
- 28 Sep 2026
- Ownership
- See footnotes
- Footnotes
- F2, F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADRX
transaction
Derivative
Series A Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -7,127,019
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 28 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 7,127,019
- Exercise price
- Footnotes
- F1, F3, F4
ADRX
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -1,333,975
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 28 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 1,333,975
- Exercise price
- Footnotes
- F1, F3, F4
ADRX
transaction
Derivative
Series B-1 Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -513,067
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 28 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 513,067
- Exercise price
- Footnotes
- F1, F3, F4
ADRX
transaction
Derivative
Series C Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -256,448
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 28 Sep 2026
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 256,448
- Exercise price
- Footnotes
- F1, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
Footnote F2
Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
Footnote F3
These securities are held directly by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("Israel GP") is the general partner of OIP II. OrbiMed Advisors Israel II Limited ("Advisors Israel") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of Carl L. Gordon, David P. Bonita, and the Reporting Person, each of whom disclaims beneficial ownership of the shares held by OIP II.
Footnote F4
Each of the Reporting Person, Israel GP, and Advisors Israel disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.